Intrapleural Staphylococcal Superantigen Induces Resolution of Malignant Pleural Effusions and a Survival Benefit in Non-Small Cell Lung Cancer

Ren, Shengxiang; Terman, David S.; Bohach, Greg; Silvers, Abraham; Hansen, Chris; Colt, Henri G.; Sahn, Steven A.

doi:10.1378/chest.126.5.1529

Cited by 61 publications

(67 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instillation of the sclerosing agent is thereafter followed by a profound inflammatory response between the layers, which, in turn, result in fibrin accumulation and pleural fibrosis. A variety of different chemicals (talc, bleomycin, tetracycline, iodopovide and others) and bacterial products (from Corynobactum parvum, Streptococcus pyogenes, Staphylococcus aureus and others) have been used in clinical studies to achieve pleurodesis [70][71][72][73]. The profound inflammatory response they cause may result in adverse events such as pain and fever but it is believed that the level of inflammation correlates with the likelihood of successful pleurodesis [74].…”

Section: Pleurodesismentioning

confidence: 99%

Malignant pleural effusion: from bench to bedside

et al. 2016

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field. @ERSpublications This review provides up to date knowledge for malignant pleural effusion covering aspects from bench to bedside http://ow.ly/10w7vN

show abstract

Section: Pleurodesismentioning

confidence: 99%

Malignant pleural effusion: from bench to bedside

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In addition, several lines of evidence support the notion that tumor cells produce mediators that sculpt the tumor microenvironment in favor of sustained growth and metastasis (9,10,16,17). Human MPE contains inflammatory cells and mediators (1,3,18), but their role in disease progression is uncertain (19)(20)(21).…”

Section: Introductionmentioning

confidence: 98%

Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion

Stathopoulos

Kollintza²,

Moschos³

et al. 2007

Cancer Research

116

View full text Add to dashboard Cite

Tumor necrosis factor (TNF)-A is present in the microenvironment of human tumors, including malignant pleural effusion (MPE). Although the cytokine is produced in the pleural cavity by both tumor and host cells, its effects on MPE formation are unknown. In these studies, we sought to determine the role of TNF-A in the pathogenesis of MPE and to assess the therapeutic effects of its neutralization in a preclinical model. For this, MPEs were generated in immunocompetent mice using intrapleural injection of mouse lung adenocarcinoma cells. The roles of tumor-and host-derived TNF-A were assessed using combined experimentation with TNF-a gene-deficient mice and in vivo TNF-A neutralization.

show abstract

“…One of the patients in the CR group has survived 36 months. None of the 13 talc-treated patients survived >6 months [36]. These data seem to corroborate that nonspecific activation of the immune system can have significant effects not only on local control of MPE but also potentially on survival.…”

Section: Ip Immunotherapymentioning

confidence: 66%

“…Ren et al [36] instilled staphylococcal super antigen (SSAg) into the pleural space of patients with stage IIIb lung cancer with poor performance status (ECOG PS ≥2). Fourteen consecutive unselected patients received IP SSAg once or twice weekly until pleural effusions resolved.…”

Section: Ip Immunotherapymentioning

confidence: 99%

Novel Intrapleural Therapies for Malignant Diseases

Haas¹,

Sterman²

2012

Respiration

View full text Add to dashboard Cite

Pleural malignancies, either primary or metastatic, are common and problematic clinical issues in thoracic oncology and pulmonary medicine. Malignant pleural mesothelioma and metastatic pleural effusions often present late in the course of a disease and have a dramatic impact on the patient’s quality of life and survival. Novel approaches to manage mesothelioma and malignant pleural effusions are desperately needed and the pleural space provides a unique platform as an easily accessible body cavity for developing and assessing these treatments and their responses. In this review, we discuss the unique intrapleural chemotherapeutic, immunotherapeutic and genetic treatments that have been investigated, as well as those under current clinical development. While responses have been demonstrated to variable degrees with all these approaches, an integrated multimodality approach incorporating these methods with other anti-neoplastic interventions ultimately will ensure the best responses and patient outcomes.

show abstract

Intrapleural Staphylococcal Superantigen Induces Resolution of Malignant Pleural Effusions and a Survival Benefit in Non-Small Cell Lung Cancer

Cited by 61 publications

References 39 publications

Malignant pleural effusion: from bench to bedside

Malignant pleural effusion: from bench to bedside

Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion

Novel Intrapleural Therapies for Malignant Diseases

Contact Info

Product

Resources

About